2-ButynaMide, N-[4-[(3-broMophenyl)aMino]-6-quinazolinyl]- Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Overactivity of epidermal growth factor receptor (EGFR) tyrosine kinase activity has been associated with a number of cancers. CL 387,785 is a potent, irreversible inhibitor of EGFR kinase activity (IC₅₀ = 370 pM). It blocks EGF-stimulated autophosphorylation of receptors in cells (IC₅₀ = 5 nM) and halts cell cycling in cells that overexpress EGFR or c-ErbB2 (IC₅₀s = 31-125 nM). CL 387,785 profoundly blocks the growth of EGFR-overexpressing tumors in nude mice when given orally at 80 mg/kg/day for 10 days.

Verwenden

CL-387785 (EKI-785) is an irreversible and selective EGFR inhibitor showing activity against mutations of the receptor. Potential therapeutic against various type of cancer, including lung cancer.

Definition

ChEBI: A member of the class of quinazolines that is 4,6-diaminoquinazoine in which the one of the hydrogens attached to the amino group at position 4 has been replaced by a m-bromophenyl group while one of the hydrogens attached to the amino group a position 6 has been replaced by a but-2-ynoyl group.

2-ButynaMide, N-[4-[(3-broMophenyl)aMino]-6-quinazolinyl]- Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

2-ButynaMide, N-[4-[(3-broMophenyl)aMino]-6-quinazolinyl]- Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
ATK CHEMICAL COMPANY LIMITED	+undefined-21-51877795	ivan@atkchemical.com	China	32956	60
Hubei Jusheng Technology Co.,Ltd.	18871490254	linda@hubeijusheng.com	CHINA	28172	58
BOC Sciences	+1-631-485-4226	inquiry@bocsci.com	United States	19553	58
career henan chemical co	+86-0371-86658258 +8613203830695	factory@coreychem.com	China	29810	58
SHANGHAI T&W PHARMACEUTICAL CO., LTD.	+86-021-61551413 +8618813727289	contact@trustwe.com	China	5738	58
Tianjin Xinshengjiahe Science & Technology Development Co,.Ltd	+86-86-22-87899925 +86-8618522618860	18522618860@163.com	China	694	58
TargetMol Chemicals Inc.	+1-781-999-5354 +1-00000000000	marketing@targetmol.com	United States	32161	58
Dideu Industries Group Limited	+86-29-89586680 +86-15129568250	1026@dideu.com	China	22787	58
Shenzhen Shengda Pharma Limited	755-85269922 +8613424394241	sales@shengdapharm.com	CHINA	310	58
Zhejiang J&C Biological Technology Co.,Limited	+1-2135480471 +1-2135480471	sales@sarms4muscle.com	China	10473	58

194423-06-8()Verwandte Suche:

---

• CL-387785 (EKI-785)
• N-(4-(3-bromophenylamino)quinazolin-6-yl)but-2-ynamide
• N-[4-[(3-broMophenyl)aMino]-6-quinazolinyl]-2-ButynaMide CL-387785
• 2-ButynaMide, N-[4-[(3-broMophenyl)aMino]-6-quinazolinyl]-
• CL-387785, >=98%
• CL-38875
• EKB 785
• WAY-EKI 785
• EKI-785 CL-38875
• CL-387
• 785
• EKI-785; WAY-EKI 785; CL387785; CL 387785; EKI785; WAY-EKI785; EKI 785;CL-387;785
• CS-1630
• N-[4-(3-bromoanilino)quinazolin-6-yl]but-2-ynamide
• -387785
• 2-ButynaMide, N-[4-[(3-broMophenyl)aMino]-6-quinazolinyl]- USP/EP/BP
• CL-387785,ErbB-1,HER1,CL387785,EGFR,EKI785,inhibit,Inhibitor,CL 387785,EKI 785,Epidermal growth factor receptor
• 194423-06-8
• Inhibitors